COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer

Authors
Category Primary study
JournalGYNECOLOGIC ONCOLOGY
Year 2024
This article has no abstract
Epistemonikos ID: 1f92fccd3176afb0dbc0b981803b7c3bd822b750
First added on: Feb 19, 2025